Lecanemab Linked to Death in AD Patient With Stroke Given tPA

A case report links the investigational Alzheimer's drug to numerous severe intracerebral hemorrhages during thrombolysis treatment.

Related Keywords

Chicago ,Illinois ,United States ,Arizona ,California ,Phoenix ,New Haven ,Connecticut ,Yale University ,San Francisco ,Sherry Hsiang Yi Chou ,Marwan Sabbagh ,Michael Weiner ,University Of California ,Barrow Neurological Institute ,Yale University School Of Medicine ,Drug Administration ,Northwestern University Feinberg School Of Medicine ,New England Journal ,Prescription Drug User Fee Act ,Northwestern University Feinberg School ,Early Alzheimer ,Yale University School ,Medscape Cardiology ,Alzheimers Disease ,Lzheimer Disease ,Stroke Risk ,Hemorrhagic Stroke ,Patient Safety ,Experimental Drug ,Monoclonal Antibody ,Etuximab ,Ituximab ,Antidementia Agents ,Adverse Effects ,Side Effects ,Amyloid Plaque ,Tissue Plasminogen Activator Tpa ,Pa Tissue Plasminogen Activator ,Intracerebral Hemmorhage ,Brain ,Vasculitis ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Dementia ,Elder ,